NCT01852864

Degarelix Before Radical Prostatectomy

A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of Cambridge · Academic / Other
• Sex: Male
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The biological effects of castration on prostate cancers will be studies by administration of degarelix prior to radical prostatectomy. The effects will be studied by analysis of gene expression and immunohistochemistry focusing on markers of proliferation and apoptosis of samples taken at the time of radical prostatectomy (7 days after administration of degarelix). Tumours from patients treated with neo-adjuvant degarelix will be compared with tumours from patients who have not been medically castrated.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	240mg degarelix s.c. injection	7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.

Timeline

• Start date: 2011-07-01
• Primary completion: 2015-07-01
• Completion: 2015-12-01
• First posted: 2013-05-14
• Last updated: 2014-12-16

Locations

1 site across 1 country: United Kingdom